Teacher Retirement System of Texas increased its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 42.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 32,963 shares of the company's stock after buying an additional 9,769 shares during the period. Teacher Retirement System of Texas' holdings in Vaxcyte were worth $2,698,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds also recently bought and sold shares of PCVX. Diversified Trust Co purchased a new position in shares of Vaxcyte in the 4th quarter valued at $1,433,000. China Universal Asset Management Co. Ltd. increased its position in Vaxcyte by 23.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock valued at $2,163,000 after buying an additional 4,962 shares in the last quarter. Citigroup Inc. raised its stake in Vaxcyte by 33.0% in the third quarter. Citigroup Inc. now owns 220,543 shares of the company's stock valued at $25,201,000 after buying an additional 54,748 shares during the last quarter. TimesSquare Capital Management LLC boosted its holdings in Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares in the last quarter. Finally, Principal Financial Group Inc. grew its stake in shares of Vaxcyte by 186.2% during the third quarter. Principal Financial Group Inc. now owns 52,702 shares of the company's stock worth $6,022,000 after acquiring an additional 34,287 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on PCVX shares. Guggenheim reissued a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $140.00 target price on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, December 20th. They set a "buy" rating and a $135.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $147.50.
Read Our Latest Stock Report on Vaxcyte
Vaxcyte Stock Performance
NASDAQ PCVX traded down $1.31 during trading on Friday, reaching $69.46. 660,934 shares of the company's stock were exchanged, compared to its average volume of 980,702. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The stock has a market cap of $8.94 billion, a P/E ratio of -15.10 and a beta of 1.02. The company has a 50 day moving average price of $80.07 and a two-hundred day moving average price of $92.52.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.16) by $0.14. Research analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Insider Buying and Selling
In related news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, COO Jim Wassil sold 8,000 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. This represents a 4.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 46,250 shares of company stock valued at $3,840,018 over the last quarter. 3.10% of the stock is currently owned by insiders.
Vaxcyte Profile
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Further Reading
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
